Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amlodipine + valsartan + hydrochlorothiazide is a fixed-dose combination oral medication used to treat high blood pressure (hypertension). It combines three antihypertensive agents with complementary mechanisms of action: - **Amlodipine** is a calcium channel blocker (CCB) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in vasodilation and reduced blood pressure. - **Valsartan** is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, preventing vasoconstriction and lowering blood pressure. - **Hydrochlorothiazide** is a thiazide diuretic that acts on the distal renal tubules to inhibit sodium reabsorption, increasing excretion of sodium and water, which reduces plasma volume and decreases blood pressure. This triple combination targets different pathways involved in hypertension for additive or synergistic effects. It is indicated for patients whose blood pressure is not adequately controlled by dual therapy or as initial therapy when clinically appropriate. The product is available as film-coated tablets in various strengths[1][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amlodipine + valsartan + hydrochlorothiazide.